Key result
Basal normoglycemia with insulin or chlorpropamide normalizes platelet aggregation rates in type 2 diabetes.
Why the study?
Non-insulin-dependent diabetic subjects thought to be well-controlled on diet alone have raised basal plasma glucose levels associated with abnormal platelet aggregation rates.
Does inducing basal normoglycemia with ultralente insulin or chlorpropamide reduce in vitro platelet aggregation rates in non-insulin-dependent diabetic subjects?
Does inducing basal normoglycemia with ultralente insulin or chlorpropamide reduce in vitro platelet aggregation rates in non-insulin-dependent diabetic subjects?
Achieving basal normoglycemia in non-insulin-dependent diabetes significantly reduces abnormally raised platelet aggregation rates, suggesting that the degree of glucose control is the primary driver of reduced platelet hyperreactivity.
Answers are grounded in this paper and cite their sources.
May support glycemic control to normalize platelet function in type 2 diabetes; leaves open whether this reduces cardiovascular events.
Non-insulin-dependent diabetic subjects had abnormally raised in vitro platelet aggregation rates to collagen or ristocetin when thought to be "well-controlled" on diet alone but shown to have raised basal plasma glucose levels. Basal normoglycemia, induced with either ultralente insulin or chlorpropamide, was associated with a significant reduction of the enhanced platelet aggregation rates to normal. Some sulfonylurea drugs have been reported to have specific anti-platelet aggregatory properties, but the degree of plasma glucose control is probably more relevant.
No takes yet. Share an insight, caveat, or question.
Evans et al. (1982) studied Non-insulin-dependent Diabetes. Basal normoglycemia induced with ultralente insulin or chlorpropamide vs. Baseline (diet alone with raised basal plasma glucose) was evaluated on In vitro platelet aggregation rates to collagen or ristocetin. Inducing basal normoglycemia with ultralente insulin or chlorpropamide significantly reduced enhanced in vitro platelet aggregation rates to normal in non-insulin-dependent diabetic subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: